Markers such as vimentin, ZEB, TWIST, and SLUG were seen in EGFR-mutated lung cancer cells upon EGFR TKI (Tyrosine Kinase Inhibitor) therapy, underscoring the role of phenotypic plasticity in therapeutic resistance [44,45,46]. Here, EGFR is linked to lung carcinoma.